Trial Profile
A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Subjects Infected With Respiratory Syncytial Virus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Rilematovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Janssen Research & Development; Janssen Sciences Ireland UC
- 01 Oct 2023 Results assessing the antiviral effect, clinical outcomes, and safety of the respiratory syncytial virus (RSV) fusion inhibitor rilematovir in non-hospitalized RSV-infected adults, published in the Clinical Microbiology and Infection
- 21 Jan 2020 Status changed from active, no longer recruiting to completed.
- 19 Jan 2020 According to EudraCT database this trial has been completed in Spain.